.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The SAXOPHONE trial recently highlighted the safety of using apixaban in pediatric heart disease for thromboprophylaxis. Within this primary trial design, researchers included an exploratory substudy to evaluate the drug's impact on surrogate biomarkers of efficacy. Specifically, the medical team monitored changes in d-dimer levels, thrombin generation assay (TGA) parameters, and various hemostatic proteins. By comparing apixaban to standard-of-care treatments like vitamin K antagonists (VKAs) and low-molecular-weight heparin, the study provides valuable insights into pediatric anticoagulation management.
The results showed that d-dimer levels decreased significantly at the six-month mark across all treatment groups. Furthermore, the findings indicated that apixaban in pediatric heart disease significantly prolonged the TGA lag time and the time to peak compared to VKAs. This suggests a potent reduction in hypercoagulability. Although apixaban reduced peak thrombin similarly to VKAs in anticoagulant-naïve patients, it effectively preserved the endogenous thrombin potential. Consequently, these changes align with observations previously recorded in adult populations, supporting the clinical efficacy of this direct oral anticoagulant.
Regarding hemostatic proteins, apixaban decreased fibrinogen and factor VIII levels at six months. However, the drug did not significantly alter protein C or protein S levels. Additionally, prior exposure to VKAs caused noticeable carryover effects, which suppressed baseline d-dimer and other protein levels. Overall, the substudy supports the primary outcomes of the SAXOPHONE trial. It reinforces the favorable risk-benefit profile of apixaban as a convenient and effective option for children requiring long-term anticoagulation. These findings offer clinicians a more predictable alternative to traditional therapies that often require frequent monitoring.
It demonstrates that apixaban successfully reduces markers of hypercoagulability, such as d-dimer, and prolongs thrombin generation lag time in children with heart disease.
According to the trial data, apixaban does not have a significant effect on protein C or protein S levels in pediatric patients with heart disease.
The study indicates that apixaban provides similar reductions in hypercoagulability and peak thrombin as vitamin K antagonists, while offering a more favorable safety and convenience profile.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional recommendation. Always seek the advice of a qualified healthcare provider regarding any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A substudy of the SAXOPHONE trial reveals how apixaban affects hemostatic biomarkers and thrombin generation in children with heart disease....
5 months ago
A new study reveals that lipid-related metabolic dysregulation, marked by elevated TG/HDL-C ratio and glymphatic changes, independently impacts survival in idiopathic normal pressure hydrocephalus.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
